K
Kenneth C. Huber
Researcher at Mount Sinai St. Luke's and Mount Sinai Roosevelt
Publications - 24
Citations - 3964
Kenneth C. Huber is an academic researcher from Mount Sinai St. Luke's and Mount Sinai Roosevelt. The author has contributed to research in topics: Atrial fibrillation & Myocardial infarction. The author has an hindex of 13, co-authored 22 publications receiving 3371 citations.
Papers
More filters
Journal ArticleDOI
Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial
David R. Holmes,Saibal Kar,Matthew J. Price,Brian Whisenant,Horst Sievert,Shephal K. Doshi,Kenneth C. Huber,Vivek Y. Reddy +7 more
TL;DR: In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke prevention or SE >7 days' post-procedure in patients with NVAF who do not have an absolute contraindication to short-termwarfarin therapy.
Journal ArticleDOI
Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation A Randomized Clinical Trial
Vivek Y. Reddy,Horst Sievert,Jonathan L. Halperin,Shephal K. Doshi,Maurice Buchbinder,Petr Neuzil,Kenneth C. Huber,Brian Whisenant,Saibal Kar,Vijay Swarup,Nicole Gordon,David R. Holmes,Investigators +12 more
TL;DR: Percutaneous LAA closure met criteria for both noninferiority and superiority, compared with warfarin, for preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as superiority for cardiovascular and all-cause mortality.
Journal ArticleDOI
Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience
James A. Suero,Steven P. Marso,Philip G. Jones,Steven B. Laster,Kenneth C. Huber,Lee V. Giorgi,Warren L. Johnson,Barry D. Rutherford +7 more
TL;DR: A successfully revascularized CTO confers a significant 10-year survival advantage compared with failed revascularization and success rates have continued to improve without an accompanying increase in MACE rates.
Journal ArticleDOI
Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients With Atrial Fibrillation 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) Trial
Vivek Y. Reddy,Shephal K. Doshi,Horst Sievert,Maurice Buchbinder,Petr Neuzil,Kenneth C. Huber,Jonathan L. Halperin,David R. Holmes +7 more
TL;DR: In this article, a multicenter PROTECT AF study was conducted to determine whether percutaneous left atrial appendage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atrial fibrillation.
Journal ArticleDOI
Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction.
Roberto A. Corpus,John A. House,Steven P. Marso,J. Aaron Grantham,Kenneth C. Huber,Steven B. Laster,Warren L. Johnson,William C. Daniels,Charles W. Barth,Lee V. Giorgi,Barry D. Rutherford +10 more
TL;DR: Data suggest that in patients with MVD, PCI should be directed at the IRA only, with decisions about PCI of non-culprit lesions guided by objective evidence of residual ischemia at late follow-up.